Inside the box: Acoustic ejection mass spectrometry for drug discovery by Kirsten Craven | Feb 12, 2025 | Blogs, Discovery, Echo MS, Pharma, QA/QCOn average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
Relative migration time by Rahima Danishmand | Mar 7, 2024 | CE, QA/QC, Questions, SCIEX OS softwareHow do I set up my processing method to calculate the RRT of the main peak to 10kD in karat 32 software?
What have we learned from the nitrosamine crisis? by Neil Walsh | Jan 30, 2023 | Blogs, Development, Pharma, QA/QCThe pharmaceutical industry is facing an ongoing issue with genotoxic impurities (GTIs). Over the past year, we have witnessed genotoxic impurities affect several drugs, including those used to treat elevated blood pressure, heartburn and acid reflux. Angiotensin II...
Developing a method for nitrosamine analysis in pharmaceutical products by Neil Walsh | Jan 22, 2021 | Blogs, Development, Pharma, QA/QCIn our previous blogs we discussed the need for a more comprehensive approach for monitoring contaminants in finished drug products.1,2 Here we cover a generalized approach for the targeted, quantitative LC-MS/MS analysis of several commonly encountered nitrosamines in pharmaceuticals and ways to address specific challenges with their analysis.
Are we proactively solving the nitrosamine crisis? by Neil Walsh | May 8, 2020 | Blogs, Development, Pharma, QA/QCIn my previous blog, I spoke about the FDA recall of angiotensin II receptor blockers like losartan. This recall was due to the presence of genotoxic nitrosamines. Is a proactive approach the way to mitigate risk? Recently, the FDA has re-issued the 2018 guidance to...